Treatment of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) with a Polypeptide

Case ID:
UA20-216
Invention:

The SARS-CoV-2 virus binds to ACE2, a cell surface protein receptor. The ACE2 binding reduces the ability of ACE2 to break down Angiotensin-II (Ang-II). Ang-II is a potent vasoconstrictor that can increase lung injury and lung edema, increase blood pressure, and can be harmful to organ function at high concentrations.

This technology administers a polypeptide through a pharmaceutically acceptable salt form to patients infected with the SARS-CoV-2 coronavirus. The polypeptide works to counteract the harmful effects of Ang-II and thus is an effective treatment for coronavirus symptoms. This substance is to be administered to the patient daily for at least one week to achieve the intended results.

Background:
In March 2020, SARS-CoV-2, a novel coronavirus, became a global pandemic and since then has infected more than 92 million people worldwide, killing nearly 2 million of those people. Even over a year since the first SARS-CoV-2 was reported, there are still very few treatment options available to counteract the negative effects of the viral infection. Therefore, it is imperative to develop effective treatments for SARS-CoV-2. This treatment also can be effective against other coronaviruses.

This treatment technology is rapidly metabolized in the blood into biologically active fragments and can be continuously infused by any suitable route that permits such continuous infusion, including intravenously. It can be used to treat a variety of symptoms of coronavirus infections by improving the functions of the lungs, kidneys, bone marrow, coagulation parameters, brain, and heart.

Applications:

  • Treatment for coronavirus infection, including SARS-CoV-2
  • Improves function of:
    • lungs, kidneys, bone marrow, coagulation parameters, brain, and heart
  • Counteracts harmful effects of increased concentrations of angiotensin II


Advantages:

  • Permitted for continuous infusion
  • Rapidly metabolized
Patent Information:
Contact For More Information:
Katherine Kuhns
Licensing Manager, UAHS-TLA
The University of Arizona
katiekuhns@email.arizona.edu
Lead Inventor(s):
Kathleen Rodgers
Sairam Parthasarathy
Gere deZerega
Keywords: